TSO3 develops innovative low temperature sterile reprocessing solutions for medical devices.
TSO3 develops innovative low temperature sterile reprocessing solutions for medical devices.Through superior and innovative low-temperature sterile reprocessing solutions for medical devices, we offer sterility and economic efficiency. This means better and more accessible medical care.Founded in 1998, TSO3 originally developed a unique sterilization process based on only ozone as the sterilizing agent. It offered major savings over competing low-temperature sterilization methods, greater safety for both users and patients, and was considered a “green” technology.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Aug 1, 2018 | Post-IPO Debt | $20M | — | — | — | Detail |
Mar 10, 2010 | Post-IPO Equity | $120K | — | — | — | Detail |
Oct 12, 2001 | IPO | — | — | — | — | Detail |